Paul Rogowski1, Mack Roach2, Nina-Sophie Schmidt-Hegemann3, Christian Trapp3, Rieke von Bestenbostel3, Run Shi3, Alexander Buchner4, Christian Stief4, Claus Belka3,5, Minglun Li3. 1. Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. paul.rogowski@med.uni-muenchen.de. 2. Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Suite H 1031, San Francisco, CA, 94143-1708, USA. 3. Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 4. Department of Urology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 5. German Cancer Consortium (DKTK), Munich, Germany.
Abstract
BACKGROUND: Due to improved imaging sensitivity, the term "oligometastatic" prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease: (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients. METHODS: A systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivity, as well as pattern of recurrence. FINDINGS: Evidence consists largely of retrospective case series and no consistent precise definition of oligometastasis exists, however, most investigators seem to acknowledge the need to distinguish between patients presenting with what is frequently called "synchronous" versus "metachronous" oligometastatic disease. Available data on radiotherapy as MDT demonstrate high local control rates and a small but relevant proportion of patients without progressive disease after 2 years. This holds true for both hormone sensitive and castration resistant prostate cancer diseases. The use of 68Ga-PSMA PET/CT for staging increased dramatically. Radiation doses and field sizes varied considerably among the studies. The search for relevant prognostic and predictive factors is ongoing. CONCLUSIONS: To our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.
BACKGROUND: Due to improved imaging sensitivity, the term "oligometastatic" prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease: (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients. METHODS: A systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivity, as well as pattern of recurrence. FINDINGS: Evidence consists largely of retrospective case series and no consistent precise definition of oligometastasis exists, however, most investigators seem to acknowledge the need to distinguish between patients presenting with what is frequently called "synchronous" versus "metachronous" oligometastatic disease. Available data on radiotherapy as MDT demonstrate high local control rates and a small but relevant proportion of patients without progressive disease after 2 years. This holds true for both hormone sensitive and castration resistant prostate cancer diseases. The use of 68Ga-PSMA PET/CT for staging increased dramatically. Radiation doses and field sizes varied considerably among the studies. The search for relevant prognostic and predictive factors is ongoing. CONCLUSIONS: To our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.
Authors: Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin Journal: Eur Urol Date: 2017-06-24 Impact factor: 20.096
Authors: Ulrike Schick; Sandra Jorcano; Philippe Nouet; Michel Rouzaud; Hansjoerg Vees; Thomas Zilli; Osman Ratib; Damien C Weber; Raymond Miralbell Journal: Acta Oncol Date: 2013-04-02 Impact factor: 4.089
Authors: Piet Ost; Barbara Alicja Jereczek-Fossa; Nicholas Van As; Thomas Zilli; Alexander Muacevic; Kenneth Olivier; Daniel Henderson; Franco Casamassima; Roberto Orecchia; Alessia Surgo; Lindsay Brown; Alison Tree; Raymond Miralbell; Gert De Meerleer Journal: Eur Urol Date: 2015-07-16 Impact factor: 20.096
Authors: Matthijs Cysouw; Esther Bouman-Wammes; Otto Hoekstra; Alfons van den Eertwegh; Maartje Piet; Jeroen van Moorselaar; Ronald Boellaard; Max Dahele; Daniela Oprea-Lager Journal: Int J Radiat Oncol Biol Phys Date: 2018-02-13 Impact factor: 7.038
Authors: Jonathan L Muldermans; Lindsay B Romak; Eugene D Kwon; Sean S Park; Kenneth R Olivier Journal: Int J Radiat Oncol Biol Phys Date: 2016-01-29 Impact factor: 7.038
Authors: Nicola Fossati; Nazareno Suardi; Giorgio Gandaglia; Carlo A Bravi; Matteo Soligo; R Jeffrey Karnes; Shahrokh Shariat; Antonino Battaglia; Wouter Everaerts; Steven Joniau; Hendrik Van Poppel; Nieroshan Rajarubendra; Inderbir S Gill; Alessandro Larcher; Alexander Mottrie; Maximilian Schmautz; Axel Heidenreich; Almut Kalz; Daniar Osmonov; Klaus-Peter Juenemann; Annika Herlemann; Christian Gratzke; Christian Stief; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2018-10-06 Impact factor: 24.267
Authors: Goda Kalinauskaite; Carolin Senger; Anne Kluge; Christian Furth; Markus Kufeld; Ingeborg Tinhofer; Volker Budach; Marcus Beck; Alexandra Hochreiter; Arne Grün; Carmen Stromberger Journal: PLoS One Date: 2020-10-21 Impact factor: 3.240
Authors: Ryan Phillips; William Yue Shi; Matthew Deek; Noura Radwan; Su Jin Lim; Emmanuel S Antonarakis; Steven P Rowe; Ashley E Ross; Michael A Gorin; Curtiland Deville; Stephen C Greco; Hailun Wang; Samuel R Denmeade; Channing J Paller; Shirl Dipasquale; Theodore L DeWeese; Daniel Y Song; Hao Wang; Michael A Carducci; Kenneth J Pienta; Martin G Pomper; Adam P Dicker; Mario A Eisenberger; Ash A Alizadeh; Maximilian Diehn; Phuoc T Tran Journal: JAMA Oncol Date: 2020-05-01 Impact factor: 31.777
Authors: A G Morganti; G Macchia; F Deodato; D Pezzulla; S Cilla; M Ferro; C Romano; P Bonome; M Buwenge; A Zamagni; L Strigari; V Valentini Journal: Clin Transl Oncol Date: 2022-01-04 Impact factor: 3.405
Authors: Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu Journal: World J Urol Date: 2022-10-02 Impact factor: 3.661
Authors: Paul Rogowski; Christian Trapp; Rieke von Bestenbostel; Dinah Konnerth; Sebastian Marschner; Nina-Sophie Schmidt Hegemann; Claus Belka; Minglun Li Journal: Strahlenther Onkol Date: 2022-04-01 Impact factor: 4.033
Authors: Paul Rogowski; Christian Trapp; Rieke von Bestenbostel; Nina-Sophie Schmidt-Hegemann; Run Shi; Harun Ilhan; Alexander Kretschmer; Christian Stief; Ute Ganswindt; Claus Belka; Minglun Li Journal: Radiat Oncol Date: 2021-06-30 Impact factor: 3.481